XML 24 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities    
Net loss $ (45,529) $ (52,666)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 1,167 2,499
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 4,183 5,762
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 351 1,060
Change in fair value - Senior Secured Convertible Note (5,394) 2,980
Loss on issue - Senior Secured Convertible Note 1,111
Debt extinguishment loss - Senior Secured Convertible Note 5,167 26
APA-RDx: Issue common stock - termination payment 713
Amortization of common stock payment for vendor service agreement 346 23
Changes in operating assets and liabilities:    
Accounts receivable (28)
Prepaid expenses and other current assets 1,159 (1,160)
Accounts payable 96 89
Accrued expenses and other current liabilities (1,012) 2,394
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee (4,674) 4,380
Net cash flows used in operating activities (44,140) (32,817)
Cash flows from investing activities    
Purchase of equipment (296) (221)
Purchase of intellectual property from PAVmed Inc. (350)
Net cash flows used in investing activities (646) (221)
Cash flows from financing activities    
Proceeds – issue of preferred stock 29,798 18,625
Proceeds – issue of Senior Secured Convertible Notes 21,615 10,000
Payment – repayment of Senior Secured Convertible Note (3,616)
Proceeds – issue of common stock – At-The-Market Facility 284
Proceeds – exercise of stock options 4
Proceeds – issue common stock – Employee Stock Purchase Plan 447 551
Net cash flows provided by financing activities 48,248 29,460
Net increase (decrease) in cash 3,462 (3,578)
Cash, beginning of period 18,896 22,474
Cash, end of period $ 22,358 $ 18,896